Abstract
Background Evidence on Long COVID remains limited in sub-Saharan countries. This study aimed to explore the occurrence of COVID-19-related symptoms and factors affecting recovery and Long COVID severity in Nairobi, Kenya.
Methods A prospective cohort of individuals testing positive for SARS-CoV-2 between February 2022 and February 2023 were followed until June 2023. COVID-19-related symptoms were assessed every three months. Time to recovery was analyzed using survival analysis, while factors affecting recovery and Long COVID severity using Cox proportional hazard and Poisson regression, respectively.
Results 42/291 (14%) participants had severe/critical SARS-CoV-2 infection, 59.1% were female and median age was 34. At 6 and 12 months post-positive PCR, 53.1% and 33.5% of participants had ≥1 COVID-19-related symptoms, respectively. Fatigue (40.2%), pain (36.8%), sore throat (36.8%), headaches (36.4%), and loss of strength (31.6%) were the most frequently reported COVID-19-related symptoms. Median time to recovery was longer in symptomatic participants with severe/critical SARS-CoV-2 infection than those with mild/moderate (234 vs 206 days respectively, p=0.016). Participants aged 40-64 years experienced slower recovery than those aged <40 years (aHR=0.635 [95%CI, 0.429;0.941]) and those with tertiary education recovered faster than those with primary education (aHR=1.869 [95%CI, 1.050;3.327]). Long COVID severity was associated with female sex (aIRR=1.413 [95%CI; 1.089;1.833]), tertiary education (aIRR, 0.525 [95%CI, 0.350;0.786]), and ≥1 comorbidity (aIRR=2.540 [95%CI, 1.377;4.687]).
Conclusions Our findings suggest Long COVID presents a substantial, under-researched disease burden in Kenya. Risk factors for Long COVID are similar to those in high-income countries (HICs). Tailored prevention and support strategies for high-risk groups are needed.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study was funded by Stichting Joep Lange Institute of Global Health, Development, and the Dutch Ministry of Foreign Affairs
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethics committee of Kenya Medical Research Institute gave ethical approval for this work
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Paper in collection COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, University of Washington, and Vrije Universiteit Amsterdam.
Subject Area
Reviews and Context
0
Comment
0
TRIP Peer Reviews
0
Community Reviews
0
Automated Services
0
Blogs/Media
Author Videos